Get the Stockscreener App
2.532
2.00%
0.032
Immix Biopharma Inc stock is traded at $2.532, with a volume of 184.32K.
It is up +2.00% in the last 24 hours and up +21.43% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$2.50
Open:
$2.58
24h Volume:
184.32K
Relative Volume:
0.69
Market Cap:
$73.62M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-2.7522
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
+13.59%
1M Performance:
+21.43%
6M Performance:
+62.94%
1Y Performance:
+75.86%
1-Day Range:
$2.51
$2.60
1-Week Range:
$2.26
$2.82
52-Week Range:
$1.34
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.5533 | 82.59M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.45 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.17 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immix Biopharma Inc Stock (IMMX) Latest News
Using AI based signals to follow Immix Biopharma Inc.July 2025 Catalysts & Community Consensus Stock Picks - newser.com
What analysts say about Immix Biopharma Inc stockSector-Based Investing & Low Cost Wealth Strategies - earlytimes.in
Using flow based indicators on Immix Biopharma Inc.July 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
Published on: 2025-10-10 06:23:37 - newser.com
How to integrate Immix Biopharma Inc. into portfolio analysis tools2025 Year in Review & Expert Verified Movement Alerts - newser.com
Multi factor analysis applied to Immix Biopharma Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Analyzing drawdowns of Immix Biopharma Inc. with statistical tools2025 Volume Leaders & AI Driven Stock Movement Reports - newser.com
Will Immix Biopharma Inc. stock outperform growth indexesWall Street Watch & Reliable Intraday Trade Alerts - newser.com
Immix Biopharma's (IMMX) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Will Immix Biopharma Inc. benefit from macro trendsJuly 2025 Gainers & Free Real-Time Volume Trigger Notifications - newser.com
Comparing Immix Biopharma (NASDAQ:IMMX) & Candel Therapeutics (NASDAQ:CADL) - Defense World
Is Immix Biopharma Inc a good long term investmentLong-Term Investment Plans & Exceptional Profit Trading - earlytimes.in
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting - GlobeNewswire
Immix Biopharma, Inc. to Present NXC-201 Abstract at ASH 67th Annual Meeting - Quiver Quantitative
NXC-201 Abstract: Immix Biopharma to Present at ASH 67th Annual Meeting in Orlando Dec 6-9, 2025 - Stock Titan
Why Immix Biopharma Inc. stock appeals to analysts2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Why Immix Biopharma Inc. stock could benefit from AI revolutionWeekly Gains Report & Free Fast Gain Swing Trade Alerts - newser.com
Measuring Immix Biopharma Inc.’s beta against major indicesAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Immix Biopharma Inc. stock chart pattern explainedEntry Point & Verified Short-Term Plans - newser.com
Analyzing Immix Biopharma Inc. with multi timeframe chartsMarket Trend Review & Free Real-Time Volume Trigger Notifications - newser.com
Will breakout in Immix Biopharma Inc. lead to full recoveryMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference - The Manila Times
Immix Biopharma, Inc. to Host Investor Meetings at 37th Annual Piper Sandler Healthcare Conference - Quiver Quantitative
Clinical-Stage Cell Therapy Developer ImmixBio to Showcase AL Amyloidosis Pipeline at Major Healthcare Conference - Stock Titan
Real time pattern detection on Immix Biopharma Inc. stockJuly 2025 Snapshot & Free Real-Time Market Sentiment Alerts - newser.com
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):